Current Issue : January/February 2012
Web Exclusives
Feng Zeng, PhD; Russell L. Knoth, PhD; Bimal V. Patel, PharmD, MS; Edward Kim, MD, MBA; Quynh-Van Tran, PharmD, BCPP; and Yonghua Jing, PhD
Among the commercially insured, benefit restrictions can impact atypical antipsychotic medication persistence and adherence in patients who have been newly initiated on treatment.
Tammie Lee Demler, BS, PharmD, BCPP, MBA; Stephanie Keller-Wilcott, PharmD, BCPP; and Terrance J. Bellnier, RPh, MPA, FASCP
The concomitant use of intramusclar lorazepam with olanzapine or ziprasidone appears to be safe and well tolerated in severely mentally ill patients with acute agitation.
Patrick J. Dunham, BSEE; and Jeffrey M. Karkula, RPh, BSPharm
A comprehensive pharmacy-care program demonstrated substantial and sustained improvement in medication adherence, CD4 cell counts, and viral load among HIV patients receiving HAART.
Li Ma, PhD; Ning Wu, PhD; Patricia A. Russo, PhD, MSW, RN; Brooke S. Harrow, PhD; Laura A. Menditto, MBA, MPH; and Bhakti Arondekar, BPharm, MBA, PhD
Economic analysis of resource utilization and cost associated with the use of rosiglitazone versus sulfonylurea as add-on therapy among type 2 diabetes mellitus patients.
Lois E. Lamerato, PhD; Eric J. Kruep, PharmD; Susan L. Hogue, PharmD; Sham L. Chaudhari, MS; and Michael T. Eaddy, PharmD, PhD
Early rather than later initiation of 5ARI therapy reduced the likelihood of clinical progression in benign prostatic hyperplasia patients and offers substantial savings to health plans.
Supplements
Advertisement
Advertisement
